Form D · Pharmaceuticals
Ascendis Pharma A/S
Hellerup, G7 · CIK 0001612042
Offering snapshot reported Dec 9, 2014 · SEC filing
- Reported sold
- $60M Offering amount: $60M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 24, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 9, 2014 | Initial | $59,999,974 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-229723
Source: Form D, filed Dec 9, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Martin Auster | Executive |
| Albert Cha | Director |
| Edwin De Graaf | Director |
| James Healy | Director |
| Michael Wolff Jensen | Director, Executive |
| Michael Mayer | Director |
| Jan M?Ller Mikkelsen | Director, Executive |
| Martin Olin | Director |
| Grethe Rasmussen | Executive |
| Harald Rau | Executive |
| Jonathan Silverstein | Director |
| Lotte S?Nderbjerg | Executive |
| Thomas Soloway | Executive |
| Rafa?Le Tordjman | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
Tuborg Boulevard 12
Hellerup, G7, DK-2900
Hellerup, G7, DK-2900